The global gastrointestinal market is expected to grow at a CAGR of 4.5% during the forecast period, from 2021 to 2030. The prescription gastrointestinal drug segment is expected to account for the largest share of the global market in terms of revenue, followed by OTC gastrointestinal drugs and application segments. Chronic gastritis is projected to be the fastest-growing application segment during the forecast period, with a CAGR of 5.2%. North America is expected to account for the largest share in terms of revenue and Asia Pacific will be fastest-growing region in terms of revenue during 2021-2030.
Some Of The Growth Factors Of This Market:
- The global population is expected to grow by 2 billion people by 2050, which will increase the demand for food and water.
- The world's population is aging, which will lead to an increased need for healthcare services and products.
- There are more people living in urban areas than rural areas, which means that there are more opportunities for companies to sell their products in urban markets than rural markets.
- The world's middle class is growing rapidly, which means that there are more people with disposable income who can afford to buy goods and services from companies like Nestle SA (NESN). 5.There has been a shift away from traditional diets towards diets high in processed foods, sugar-sweetened beverages and red meat - all of these factors have contributed to the rise of obesity rates around the world.
Industry Growth Insights published a new data on “Gastrointestinal Market”. The research report is titled “Gastrointestinal Market research by Types (Prescription Gastrointestinal Drug, OTC Gastrointestinal Drug), By Applications (Chronic Gastritis, Functional Dyspepsia, Peptic Ulcer, Acute Gastroenteritis, Other, ), By Players/Companies AstraZenec, Sanofi, Bayer, Pfizer, GlaxoSmithKline, Teva, Zeria(Tillotts), Perrigo, Boehringer Ingelheim, Purdue Pharma, C.B. Fleet, Abbott, Jiangzhong, Xian-Janssen, ”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Gastrointestinal Market Research Report
By Type
Prescription Gastrointestinal Drug, OTC Gastrointestinal Drug
By Application
Chronic Gastritis, Functional Dyspepsia, Peptic Ulcer, Acute Gastroenteritis, Other,
By Companies
AstraZenec, Sanofi, Bayer, Pfizer, GlaxoSmithKline, Teva, Zeria(Tillotts), Perrigo, Boehringer Ingelheim, Purdue Pharma, C.B. Fleet, Abbott, Jiangzhong, Xian-Janssen,
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
241
Number of Tables & Figures
169
Customization Available
Yes, the report can be customized as per your need.
Global Gastrointestinal Market Report Segments:
The global Gastrointestinal market is segmented on the basis of:
Types
Prescription Gastrointestinal Drug, OTC Gastrointestinal Drug
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Chronic Gastritis, Functional Dyspepsia, Peptic Ulcer, Acute Gastroenteritis, Other,
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZenec
- Sanofi
- Bayer
- Pfizer
- GlaxoSmithKline
- Teva
- Zeria(Tillotts)
- Perrigo
- Boehringer Ingelheim
- Purdue Pharma
- C.B. Fleet
- Abbott
- Jiangzhong
- Xian-Janssen
Highlights of The Gastrointestinal Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Prescription Gastrointestinal Drug
- OTC Gastrointestinal Drug
- By Application:
- Chronic Gastritis
- Functional Dyspepsia
- Peptic Ulcer
- Acute Gastroenteritis
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Gastrointestinal Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Gastrointestinal refers to the digestive system. It includes the stomach, small intestine, and large intestine.
Some of the major companies in the gastrointestinal market are AstraZenec, Sanofi, Bayer, Pfizer, GlaxoSmithKline, Teva, Zeria(Tillotts), Perrigo, Boehringer Ingelheim, Purdue Pharma, C.B. Fleet, Abbott, Jiangzhong, Xian-Janssen.
The gastrointestinal market is expected to register a CAGR of 4.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Gastrointestinal Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Gastrointestinal Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Gastrointestinal Market - Supply Chain
4.5. Global Gastrointestinal Market Forecast
4.5.1. Gastrointestinal Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Gastrointestinal Market Size (000 Units) and Y-o-Y Growth
4.5.3. Gastrointestinal Market Absolute $ Opportunity
5. Global Gastrointestinal Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Gastrointestinal Market Size and Volume Forecast by Type
5.3.1. Prescription Gastrointestinal Drug
5.3.2. OTC Gastrointestinal Drug
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Gastrointestinal Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Gastrointestinal Market Size and Volume Forecast by Application
6.3.1. Chronic Gastritis
6.3.2. Functional Dyspepsia
6.3.3. Peptic Ulcer
6.3.4. Acute Gastroenteritis
6.3.5. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Gastrointestinal Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Gastrointestinal Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Gastrointestinal Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Gastrointestinal Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Gastrointestinal Demand Share Forecast, 2019-2026
9. North America Gastrointestinal Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Gastrointestinal Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Gastrointestinal Market Size and Volume Forecast by Application
9.4.1. Chronic Gastritis
9.4.2. Functional Dyspepsia
9.4.3. Peptic Ulcer
9.4.4. Acute Gastroenteritis
9.4.5. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Gastrointestinal Market Size and Volume Forecast by Type
9.7.1. Prescription Gastrointestinal Drug
9.7.2. OTC Gastrointestinal Drug
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Gastrointestinal Demand Share Forecast, 2019-2026
10. Latin America Gastrointestinal Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Gastrointestinal Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Gastrointestinal Market Size and Volume Forecast by Application
10.4.1. Chronic Gastritis
10.4.2. Functional Dyspepsia
10.4.3. Peptic Ulcer
10.4.4. Acute Gastroenteritis
10.4.5. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Gastrointestinal Market Size and Volume Forecast by Type
10.7.1. Prescription Gastrointestinal Drug
10.7.2. OTC Gastrointestinal Drug
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Gastrointestinal Demand Share Forecast, 2019-2026
11. Europe Gastrointestinal Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Gastrointestinal Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Gastrointestinal Market Size and Volume Forecast by Application
11.4.1. Chronic Gastritis
11.4.2. Functional Dyspepsia
11.4.3. Peptic Ulcer
11.4.4. Acute Gastroenteritis
11.4.5. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Gastrointestinal Market Size and Volume Forecast by Type
11.7.1. Prescription Gastrointestinal Drug
11.7.2. OTC Gastrointestinal Drug
11.8. Basis PointShare (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Gastrointestinal Demand Share, 2019-2026
12. Asia Pacific Gastrointestinal Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Gastrointestinal Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Gastrointestinal Market Size and Volume Forecast by Application
12.4.1. Chronic Gastritis
12.4.2. Functional Dyspepsia
12.4.3. Peptic Ulcer
12.4.4. Acute Gastroenteritis
12.4.5. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Gastrointestinal Market Size and Volume Forecast by Type
12.7.1. Prescription Gastrointestinal Drug
12.7.2. OTC Gastrointestinal Drug
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Gastrointestinal Demand Share, 2019-2026
13. Middle East & Africa Gastrointestinal Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Gastrointestinal Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Gastrointestinal Market Size and Volume Forecast by Application
13.4.1. Chronic Gastritis
13.4.2. Functional Dyspepsia
13.4.3. Peptic Ulcer
13.4.4. Acute Gastroenteritis
13.4.5. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Gastrointestinal Market Size and Volume Forecast by Type
13.7.1. Prescription Gastrointestinal Drug
13.7.2. OTC Gastrointestinal Drug
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Gastrointestinal Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Gastrointestinal Market: Market Share Analysis
14.2. Gastrointestinal Distributors and Customers
14.3. Gastrointestinal Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. AstraZenec
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Sanofi
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Bayer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Pfizer
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. GlaxoSmithKline
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Teva
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Zeria(Tillotts)
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Perrigo
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Boehringer Ingelheim
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Purdue Pharma
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. C.B. Fleet
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Abbott
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Jiangzhong
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Xian-Janssen
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15.
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
